Neprilysin
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| |
| The structure of the neprilysin ectodomain in complex with a zinc-chelating inhibitor. The zinc atom is shown as a gray sphere and the inhibitor is shown in green. | |
| membrane metallo-endopeptidase
| |
| Identifiers | |
| Symbol | MME |
| Entrez | 4311 |
| HUGO | 7154 |
| OMIM | 120520 |
| RefSeq | NM_000902 |
| UniProt | P08473 |
| Other data | |
| EC number | 3.4.24.11 |
| Locus | Chr. 3 q21-q27 |
|
WikiDoc Resources for Neprilysin | |
|
Articles | |
|---|---|
|
Most recent articles on Neprilysin | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Neprilysin at Clinical Trials.gov Clinical Trials on Neprilysin at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Neprilysin
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Neprilysin Discussion groups on Neprilysin Patient Handouts on Neprilysin Directions to Hospitals Treating Neprilysin Risk calculators and risk factors for Neprilysin
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Neprilysin | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Neprilysin, also known as neutral endopeptidase (NEP), CD10, and common acute lymphoblastic leukemia antigen (CALLA), is a zinc-dependent metalloprotease enzyme that degrades a number of small secreted peptides, most notably the amyloid beta peptide whose abnormal misfolding and aggregation in neural tissue has been implicated as a cause of Alzheimer's disease. Synthesized as a membrane-bound protein, the neprilysin ectodomain is released into the extracellular domain after it has been transported from the Golgi apparatus to the cell surface. In neurons, neprilysin is regulated by the protein nicastrin, a component of the gamma secretase complex that performs a necessary step in processing amyloid precursor protein to amyloid beta.[1]
Amyloid beta regulation
Mutations in the neprilysin gene have been associated with familial forms of Alzheimer's disease,[1] and neprilysin-deficient knockout mice show both Alzheimer's-like behavioral impairment and amyloid-beta deposition in the brain,[1] providing strong evidence for the protein's association with the Alzheimer's disease process. Because neprilysin is thought to be the rate-limiting step in amyloid beta degradation,[1] it has been considered a potential therapeutic target; compounds such as the peptide hormone somatostatin have been identified that increase the enzyme's activity level.[1] One hypothesis for the strong dependence of Alzheimer's incidence on age focuses on the declining production of somatostatin the brains of elderly people, which thus depresses the activity of neprilysin and promotes aggregation of unprocessed amyloid beta.[1] Declining neprilysin activity with increasing age may also be explained by oxidative damage, known to be a causative factor in Alzheimer's disease; higher levels of inappropriately oxidized neprilysin have been found in Alzheimer's patients compared to cognitively normal elderly people.[1]
Signaling peptides
Neprilysin is also associated with other biochemical processes, and is particularly highly expressed in kidney and lung tissues. Inhibitors have been designed with the aim of developing analgesic and antihypertensive agents that act by preventing neprilysin's activity against signaling peptides such as enkephalins, substance P, endothelin, and atrial natriuretic factor.[1][1]
Associations have been observed between neprilysin expression and various types of cancer; however, the relationship between neprilysin expression and carcinogenesis remains obscure. In cancer biomarker studies, the neprilysin gene is often referred to as CD10 or CALLA. In some types of cancer, such as metastatic carcinoma and some advanced melanomas, neprilysin is overexpressed;[1] in other types, most notably lung cancers, neprilysin is downregulated, and thus unable to modulate the pro-growth autocrine signaling of cancer cells via secreted peptides such as mammalian homologs related to bombesin.[1]
References
External links
Proteins: clusters of differentiation (see also list of human clusters of differentiation) | |
|---|---|
| 1-50 | CD1 (CD1a-c, CD1d) - CD2 - CD3 - CD4 - CD5 - CD8 - CD9 - CD10 - CD11 (CD11a, CD11b, CD11c) - CD13 - CD14 - CD15 - CD16 - CD18 - CD19 - CD20 - CD21 - CD22 - CD23 - CD24 - CD25 - CD26 - CD27 - CD28 - CD29 - CD30 - CD31 - CD32 - CD33 - CD34 - CD35 - CD36 - CD37 -CD38 - CD40 - CD43 - CD44 - CD45 - CD46 - CD49 (CD49a, CD49b, CD49c, CD49d) |
| 51-100 | CD52 - CD53 - CD54 - CD55 - CD56 - CD58 - CD59 - CD61 - CD62 (CD62E, CD62L, CD62P) - CD63 - CD64 - CD66e - CD68 - CD70 - CD71 - CD72 - CD79 - CD80 - CD81 - CD82 - CD83 - CD86 - CD88 - CD89 - CD90 - CD94 - CD95 - CD97 - CD98 |
| 101-350 | CD103 - CD106 - CD114 - CD116 - CD117 - CD118 - CD120 - CD122 - CD130 - CD131 - CD132 - CD133 - CD134 - CD135 - CD137 - CD138 - CD141 - CD142 - CD143 - CD146 - CD147 - CD151 - CD152 - CD153 - CD154 - CD155 - CD162 - CD164 - CD169 - CD184 - CD206 - CD209 - CD257 - CD278 - CD281 - CD282 - CD283 - CD304 |
Tumor markers |
|---|
| Alpha-fetoprotein/AFP-L3 - CA-125 - CA 19-9 - CD30 - Autocrine motility factor - Carcinoembryonic antigen - βHCG - erbB-2 receptor - erbB-3 receptor - NANOG - Neprilysin - Normetanephrine - PCNA - Prostate specific antigen - Synaptophysin |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
